Chimeric antigen receptor (CAR) T-cells have unveiled a promising therapeutic horizon for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, immune impairment induced by cellular therapies, previous treatments and MM itself could promote infectious events. COVID-19 could evolve into a life-threating infection in R/ R MM patients who often have suboptimal responses to SARS-CoV-2 vaccines. Here, we describe a case of severe and long-lasting COVID-19 pneumonia after CAR T-cell therapy for R/R MM requiring a complex clinical management. Long-term infectious complications in MM patients undergoing CAR T-cells should be taken into consideration as they could counteract the efficacy of this new treatment.

Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight / Ielo, Claudia; Fazio, Francesca; Rocchi, Serena; Rizzello, Ilaria; Mancuso, Katia; Zamagni, Elena; Cavo, Michele; Petrucci, Maria Teresa. - In: LEUKEMIA RESEARCH REPORTS. - ISSN 2213-0489. - ELETTRONICO. - 21:(2024), pp. 100399.1-100399.4. [10.1016/j.lrr.2023.100399]

Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight

Fazio, Francesca;Rocchi, Serena;Rizzello, Ilaria;Mancuso, Katia;Zamagni, Elena;Cavo, Michele;
2024

Abstract

Chimeric antigen receptor (CAR) T-cells have unveiled a promising therapeutic horizon for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, immune impairment induced by cellular therapies, previous treatments and MM itself could promote infectious events. COVID-19 could evolve into a life-threating infection in R/ R MM patients who often have suboptimal responses to SARS-CoV-2 vaccines. Here, we describe a case of severe and long-lasting COVID-19 pneumonia after CAR T-cell therapy for R/R MM requiring a complex clinical management. Long-term infectious complications in MM patients undergoing CAR T-cells should be taken into consideration as they could counteract the efficacy of this new treatment.
2024
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight / Ielo, Claudia; Fazio, Francesca; Rocchi, Serena; Rizzello, Ilaria; Mancuso, Katia; Zamagni, Elena; Cavo, Michele; Petrucci, Maria Teresa. - In: LEUKEMIA RESEARCH REPORTS. - ISSN 2213-0489. - ELETTRONICO. - 21:(2024), pp. 100399.1-100399.4. [10.1016/j.lrr.2023.100399]
Ielo, Claudia; Fazio, Francesca; Rocchi, Serena; Rizzello, Ilaria; Mancuso, Katia; Zamagni, Elena; Cavo, Michele; Petrucci, Maria Teresa
File in questo prodotto:
File Dimensione Formato  
Severe SARS-CoV-2.pdf

accesso aperto

Descrizione: Articolo
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.29 MB
Formato Adobe PDF
1.29 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/959928
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact